TURBT (Transurethral Resection of Bladder Tumor): Procedure, Outcomes, and Follow-up — Overview, Diagnosis & Treatment Options | MyMedicPlus

Transurethral resection of bladder tumor (TURBT) is the foundational endoscopic surgical procedure for the diagnosis, pathological staging, and initial treatment of bladder cancer. It is performed via a rigid cystoscope inserted through the urethra into the bladder without any external incision. A resecting loop delivers electrical (monopolar or bipolar) current to excise visible bladder tumors and obtain deep tissue specimens including detrusor muscle (muscularis propria) — the most critical determinant of staging. TURBT serves two purposes simultaneously: therapeutic (removing all visible tumor) and diagnostic (providing tissue for histopathological grading, staging, and assessment of muscle invasion). Approximately 75% of all newly diagnosed bladder cancers are non-muscle-invasive (NMIBC) — stages Ta, T1, and carcinoma in situ (CIS) — at the time of first TURBT, and TURBT is their primary treatment. Muscle-invasive bladder cancer (MIBC, ≥T2) detected at TURBT requires further treatment (radical cystectomy or definitive chemoradiation), with TURBT serving as a diagnostic and staging procedure. Quality TURBT — including adequate muscle in the specimen — is critically important for accurate staging and appropriate subsequent management.

TURBT is indicated for all patients with a newly detected or recurrent bladder tumor. The most common underlying condition is bladder urothelial carcinoma (transitional cell carcinoma), which accounts for over 90% of bladder cancers. Risk factors for bladder urothelial carcinoma — and thus TURBT candidacy — include tobacco smoking (the strongest risk factor, accounting for ~50% of cases), occupational exposure to aromatic amines (dye, rubber, leather industries), cyclophosphamide exposure (for prior cancer treatment or autoimmune disease), prior pelvic radiation, chronic bladder irritation from calculi or indwelling catheters (associated with squamous cell carcinoma), aristolochic acid nephropathy, and Lynch syndrome. Gross painless hematuria in an adult over 35 — the most common presentation of bladder cancer — mandates cystoscopy; if a tumor is identified, TURBT is performed either at the diagnostic cystoscopy or as a scheduled procedure shortly after. Persistent irritative lower urinary tract symptoms (frequency, urgency, dysuria) without infectious cause, particularly in older smokers, also warrant cystoscopic evaluation.

Patients referred for TURBT typically present following detection of a bladder tumor at cystoscopy triggered by hematuria, abnormal urine cytology, or incidental imaging finding. Gross (visible) painless hematuria — the most common presenting symptom of bladder cancer — occurs in approximately 80–90% of cases. The hematuria may be intermittent and typically involves the entire voided stream. Irritative lower urinary tract symptoms — urgency, frequency, and dysuria — are present in up to 20–30% of patients, particularly when carcinoma in situ (CIS) is present, as CIS causes diffuse mucosal irritation. Obstructive symptoms may occur when tumors arise at the ureteral orifice. Preoperative assessment for TURBT includes general medical fitness (cardiovascular, renal function, medication review, coagulation), discontinuation of anticoagulants and antiplatelet agents per guidelines, anesthetic assessment, urine culture (treated if positive before TURBT), serum creatinine, and upper tract imaging — CT urography or ultrasound — to exclude concomitant upper tract pathology (ureteral tumor, renal mass). Urine cytology is collected. Prior cystoscopy photographs or descriptions are reviewed to plan resection technique.

TURBT is both the primary treatment and the definitive staging procedure for NMIBC. Cystoscopic examination under anesthesia before resection allows bimanual palpation of the bladder wall and a systematic assessment of all urothelial surfaces under white light cystoscopy. Enhanced cystoscopy techniques — photodynamic diagnosis (PDD/blue-light cystoscopy using hexaminolevulinate, HAL) or narrow-band imaging (NBI) — significantly improve detection of flat CIS and small satellite tumors that may be missed under white light alone. EAU guidelines recommend PDD/HAL for high-risk NMIBC. Tumor characteristics are documented: number, size, location, gross appearance (papillary vs. sessile vs. flat). The resection specimen must include detrusor muscle (muscularis propria) for adequate staging — specimens without muscle are suboptimal and mandate re-TURBT within 2–6 weeks. Pathological staging: pTa (non-invasive papillary carcinoma, confined to urothelium), pT1 (invades lamina propria, subepithelial connective tissue), pT2 (invades muscularis propria — muscle-invasive). WHO grading: low grade (LG, well differentiated) vs. high grade (HG, poorly differentiated). CIS (pTis) — flat, high-grade intraepithelial carcinoma — is identified by biopsy of erythematous or suspicious mucosa.

TURBT is performed under spinal or general anesthesia as a day-case or overnight-stay procedure. A 22–26 Fr continuous-flow resectoscope is introduced per urethra. Tumors are resected with a loop electrode using a technique that resects the tumor in layers — first the exophytic portion, then the tumor base with underlying detrusor muscle. Bipolar TURBT uses saline irrigation (safer for patients with pacemakers and reduces obturator nerve reflex). Obturator nerve block is administered for lateral wall tumors to prevent reflex leg kick during resection. Photodynamic cystoscopy (blue light) is activated when HAL is used for improved CIS detection. After resection, the tumor bed is inspected and coagulated. A Foley catheter is left in place for 24–48 hours post-operatively. Single immediate intravesical instillation of mitomycin C (MMC) within 24 hours of TURBT reduces short-term recurrence rate by approximately 35% in NMIBC without high-grade features — this is a key EAU and AUA guideline recommendation (unless perforation is suspected). For non-muscle-invasive disease, adjuvant intravesical therapy is determined by risk stratification: Low-risk (pTa LG, single small tumor): observation or single MMC instillation. Intermediate-risk (recurrent LG, pTa HG small, pT1 LG): induction course of intravesical MMC or BCG followed by maintenance. High-risk (pT1 HG, CIS, pTa HG large/multifocal): BCG induction (6 weekly instillations) + BCG maintenance (3 instillations at 3, 6, 12, 18, 24, 30, 36 months — SWOG maintenance protocol) — 1–3 years of BCG maintenance significantly reduces progression and recurrence. Re-TURBT is mandatory at 2–6 weeks for: all pT1 tumors, incomplete initial resection, absence of muscle in specimen, positive urine cytology without tumor explanation.

The prognosis of non-muscle-invasive bladder cancer (NMIBC) managed with TURBT is highly risk-stratified. Low-risk NMIBC (solitary pTa low-grade tumor, diameter <3 cm, primary occurrence) carries an excellent prognosis — 5-year disease-specific survival exceeds 95%, with recurrence in approximately 30–40% of patients but progression to muscle invasion in less than 5%. Intermediate-risk NMIBC (multifocal or recurrent low-grade pTa, or pT1 low-grade) has a 5-year progression rate of 1–7% and a recurrence rate of 40–60%, requiring intravesical mitomycin C maintenance. High-risk NMIBC — including all high-grade disease, carcinoma in situ (CIS), pT1 high-grade, and tumors with lymphovascular invasion — carries the most significant oncological risk. Without BCG, approximately 50–70% of high-risk tumors recur within 2 years and 15–20% progress to muscle-invasive bladder cancer (MIBC). BCG induction and maintenance (SWOG 8507 schedule — 3 years full-dose BCG) reduces disease recurrence by 30–40% and progression to MIBC by 30–40% compared to one-time induction alone, representing the most effective recurrence-prevention strategy available. After TURBT for MIBC (pT2–T4), the 5-year overall survival with radical cystectomy is approximately 50%, and intravesical therapy has no role. Patients who are BCG-unresponsive (failure to achieve disease-free status after adequate BCG) should be offered pembrolizumab (FDA-approved) or radical cystectomy before progressing to MIBC. Tobacco smoking is a key modifiable factor — cessation reduces both recurrence and progression risk in NMIBC survivors. Lifelong cystoscopic surveillance is the cornerstone of NMIBC management given the high recurrence rates.

Bladder cancer surveillance after TURBT is essential as recurrence rates of NMIBC at 1 year range from 15% (low-risk) to 60–70% (high-risk). Cystoscopy surveillance intervals follow NMIBC risk group: Low-risk: cystoscopy at 3 months, then if negative annually for 5 years, then discharge. Intermediate-risk: cystoscopy at 3-month intervals for 2 years, then 6-monthly for years 3–5, then annually. High-risk: 3-monthly cystoscopy for 2 years, then 6-monthly for years 3–5, then annually indefinitely. CT urography is performed annually in high-risk NMIBC (CIS, HG disease) to detect upper tract recurrence. Urine cytology accompanies cystoscopy at each visit for high-grade disease. Adherence to BCG maintenance is critical for high-risk NMIBC — completion of maintenance is associated with 30–40% lower progression risk. BCG-unresponsive NMIBC (persistent HG disease after adequate BCG) should be treated with pembrolizumab (FDA-approved) or radical cystectomy. Tobacco cessation is the most important modifiable preventive measure — continued smoking increases recurrence and progression risk. Occupational hygiene and avoidance of further carcinogen exposure are important.

Any adult experiencing painless visible (gross) hematuria — blood-colored or pink-tinged urine — should seek urgent urological evaluation including urine cytology and cystoscopy to exclude bladder cancer; do not attribute hematuria to anticoagulants or urinary tract infection without urological investigation. Microscopic hematuria (3 or more red blood cells per HPF on two consecutive urinalyses) in adults over 35, particularly in current or former smokers, requires cystoscopy and upper tract imaging. Persistent irritative lower urinary tract symptoms — frequency, urgency, dysuria — without a positive urine culture and not responding to antimicrobial therapy should prompt cystoscopy to exclude CIS. Following TURBT, any episode of gross hematuria during the surveillance period requires prompt urological review — it may represent tumor recurrence. Patients experiencing post-TURBT symptoms of urinary tract infection — fever, dysuria, cloudy urine — should seek urgent care as BCG instillation-related cystitis, chemical cystitis, or bladder infection may require treatment modification. Patients with suspected bladder perforation after TURBT (sudden onset of lower abdominal pain, distension) require emergency evaluation.